Unknown OBSERVATIONAL NCT05282875

Anti-HLA Immunization And Immunosuppressive Therapy Management In Kidney Transplant Patients Returning to Dialysis

Evolution of Anti-HLA Immunization According to Immunosuppressive Therapy Management Modalities in Kidney Transplant Patients Returning to Dialysis in Lorraine Between January 2007 and December 2019

Sponsor: Central Hospital, Nancy, France

Conditions Dialysis HLA Sensitization Immunosuppressive Agents Kidney Transplantation

Interventions management of immunosuppressive therapy

Updated 5 times since 2022 Last updated: Mar 24, 2022 Started: Feb 1, 2022 Primary completion: Mar 30, 2022 Completion: Sep 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Dialysis and HLA Sensitization, this trial is ongoing. The trial is conducted by Central Hospital, Nancy, France and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status

Status: Active Not Recruiting → Unknown Status
May 2022 — Apr 2024 [monthly]

Active Not Recruiting
Apr 2022 — May 2022 [monthly]

Active Not Recruiting

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central Hospital, Nancy, France

Data source: Central Hospital, Nancy, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nancy, France